A - 116 A Neuropsychological Testing Protocol for Assessing Lecanemab Eligibility for Alzheimer’s Disease: the First Fifty Patients

Abstract Objective Since the FDA approved lecanemab for Alzheimer’s disease (ad) treatment in 2023, neuropsychology’s role in the treatment eligibility determination process has become increasingly important. Not only is objective evidence of cognitive impairment required for the diagnosis of mild c...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Archives of clinical neuropsychology 2024-10, Vol.39 (7), p.1057-1057
Hauptverfasser:	Parks, Adam, Brunette, Amanda, Reinhart, Clare, Kreszyn, Katelynn, Townley, Ryan, Burns, Jeffrey
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!